HPV病毒负荷量与TSLC-1在宫颈鳞癌及癌前病变中的相关性研究
|
摘要
目的：探讨肺癌肿瘤抑制因子1(tumor suppressor in lung cancer-1, TSLC-1)与人乳头瘤病毒(Human papillomavirus HPV)负荷量在宫颈鳞癌及癌前病变中的相关性。
方法：收集2008—2010年就诊于兰州大学第一医院100例慢性宫颈炎、宫颈上皮内瘤变及宫颈鳞状上皮细胞癌患者的宫颈脱落上皮细胞,采用杂交捕获法检测HPV病毒负荷量,免疫组化(SP)法检测相应组织TSLC-1蛋白表达,分析二者在宫颈病变进展中的关系。
结果：100例标本HPV病毒阳性54例,1≤病毒负荷量(RUL/CO)≤100共27例,100～1000共23例,≥1000为4例,TSLC-1蛋白阴性为42例,阳性表达58例,按不同表达强度分别为“+”23例,“++”20例,“+++”15例。Spearman秩相关分析显示,HPV病毒负荷量与TSLC-1表达有相关性(rs=0.586,P<0.01)。
结论：随宫颈癌前病变进展至宫颈鳞癌,HPV病毒负荷量与TSLC-1表达减低有相关性,可将二者联合检测应用于临床,预测宫颈癌前病变的进展。
Object:To study the relationship of he viral load of Human papillomavirus (HPV) and tumor suppressor in lung cancer-1(TSLC1) during the development of cervical squamous cancer.
Methods:100specimens of tissues which had been detected the viral load of HPV by HC-Ⅱ, including squamous carcinoma of the cervix, CINs and chronic cervicitis underwent immunehistochemistry to detect the expression of TSLC1, Then, evaluate their correlations.
Results:54out of100samples were HPV DNA positive, the viral load of HPV were1≤RUL/CO≤100(27/100),100～1000(23/100),≥1000(15/100), TSLC1"-"(42/100),"+"(23/100),"++"(20/100) and "+++"(15/100), Statistical analysis for the association of TSLC1and the viral load of HPV revealed that:the expression levels of TSLC and the viral load of HPV showed a significant correlation with the differentiation degree (r=0.586, P<0.01)
Conclusions:Down-regulation of TSLC1and the viral load of HPV showed a significant correlation during the pathogenesis of Cervical intraepithelial neoplasia (CIN) and Cervical squamous cell carcinoma, to detect both of them is helpful to calculated the tendency of cervical pathological changes.
方法：收集2008—2010年就诊于兰州大学第一医院100例慢性宫颈炎、宫颈上皮内瘤变及宫颈鳞状上皮细胞癌患者的宫颈脱落上皮细胞,采用杂交捕获法检测HPV病毒负荷量,免疫组化(SP)法检测相应组织TSLC-1蛋白表达,分析二者在宫颈病变进展中的关系。
结果：100例标本HPV病毒阳性54例,1≤病毒负荷量(RUL/CO)≤100共27例,100～1000共23例,≥1000为4例,TSLC-1蛋白阴性为42例,阳性表达58例,按不同表达强度分别为“+”23例,“++”20例,“+++”15例。Spearman秩相关分析显示,HPV病毒负荷量与TSLC-1表达有相关性(rs=0.586,P<0.01)。
结论：随宫颈癌前病变进展至宫颈鳞癌,HPV病毒负荷量与TSLC-1表达减低有相关性,可将二者联合检测应用于临床,预测宫颈癌前病变的进展。
Object:To study the relationship of he viral load of Human papillomavirus (HPV) and tumor suppressor in lung cancer-1(TSLC1) during the development of cervical squamous cancer.
Methods:100specimens of tissues which had been detected the viral load of HPV by HC-Ⅱ, including squamous carcinoma of the cervix, CINs and chronic cervicitis underwent immunehistochemistry to detect the expression of TSLC1, Then, evaluate their correlations.
Results:54out of100samples were HPV DNA positive, the viral load of HPV were1≤RUL/CO≤100(27/100),100～1000(23/100),≥1000(15/100), TSLC1"-"(42/100),"+"(23/100),"++"(20/100) and "+++"(15/100), Statistical analysis for the association of TSLC1and the viral load of HPV revealed that:the expression levels of TSLC and the viral load of HPV showed a significant correlation with the differentiation degree (r=0.586, P<0.01)
Conclusions:Down-regulation of TSLC1and the viral load of HPV showed a significant correlation during the pathogenesis of Cervical intraepithelial neoplasia (CIN) and Cervical squamous cell carcinoma, to detect both of them is helpful to calculated the tendency of cervical pathological changes.
引文
[1]郎景和,子宫颈癌预防的现代策略[J]中国医学科学院学报,2007,29(5)：575—578.
[2]Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer:the size of the problem [J]. Best Pract Res Clin ObstetGynaecol,2006,20 (2):207-225.
[3]Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papillomavires 16 as a determinant for development of cervical carcinoma in situ:a nested case-control study[J].Lancet, 2000,355(9222):2189.
[6]丁素玲,高魁文.人乳头状瘤病毒感染与宫颈癌的研究进展[J].中国自然医学杂志,2005,10(2)：147.
[7]许娟秀,舒宽勇,熊树华,等.宫颈癌中表观遗传学的研究进展.国际妇产科学杂志,2008,35(3)：181.
[8]Shailja Pande,Neeraj Jain, Bhudev C. Dasl, et al. Human papillomavirus type 16 variant analysis of E6, E7. and L1 genes and long control region in biopsy samples from cervical cancer patients in North India [J]. Clinical Microbiology,2008,46 (3):1060.
[9]林晓华,吴宁,侯丽辉,等.人乳头瘤病毒与宫颈肿瘤关系的研究进展(J).医学研究生学报,2006,19(2)：183.
[10]刘宏图,人乳头瘤病毒感染与宫颈癌进展的相关性[J].中国实用妇科与产科杂志,2010,26(5)：324-327.
[11]邵华江,石一复,等.人乳头瘤病毒与子宫颈癌防治进展[J].实用肿瘤杂志,2010,26(1)：5-7.
[12]Poprdvu NC, Zimonjic D, Dipaolo JA. Viral intergration,fragilesites,and protooncogenes in human meoplasia [J]. Hum Gen,1990,84:383-386.
[13]Kalantari M, Blennow E,Hagmar B, et al. Physical state of HPV16 and chromosomal mapping of the integrated from in cervical carcinomas[J].Diagn-Mol-Pathol,2001,10(1):46-54.
[14]Thorland EC, Myers SL, Persing DH, et al. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites[J]. Cancer-Res,2000,60 (21):5916-21.
[15]Horland EC, Myers SL, Gostout BS, et al. cell surface-bindingmotifs of L2 that facilitate papillovirus infection[J]. J Virol,2003,77(6):3531-41.
[16]Wentzensen N, Vinokurov S, von Knebel doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the male lower genital tract[J]. Cancer Res,2004,64:3878-3884.
[17]李华,高国兰.HPV与宫颈癌的研究进展[J].实用癌症杂志,2007,22(4)：420.
[18]李素红,王全红.HPV与宫颈癌的研究进展[J].肿瘤研究与临床,2005,17(6)：430.
[19]孙志辉,岳天孚.人乳头瘤病毒16/18型与宫颈癌[J].国际妇产科学杂志,2010,(4)：119-123.
[20]Long Fu Xi,1,3 James P. Hughes,4 Zoe R. Edelstein,et al. Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-Year Follow-Up. The Journal of Infectious Diseases 2009; 200:1789-97.
[21]Wu YP, Chen YL, Li LY, et al. Associations of high□risk HPV types and viral load with cervical cancer in China[J]. J Clin Virol 2006,35:264-269.
[22]Xavier Carcopino, Mireille Henry, Julien Mancini,et al. Significance of HPV 16 and 18 Viral Load Quantitation in Women Referred for Colposcopy[J], Journal of Medical Virology,2010 (84):306-313.
[23]Rachel L. Winer, Tiffany G. Harris, Long Fu Xi.et al. Quantitative Human Papillomavirus 16 and 18 Levels in Incident Infections and Cervical Lesion Development[J]. Journal of Medical Virology 2009(81):713-721.
[24]Satoh H, Lamb PW, Dong JT et al. Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. Mol Carcinog 1993; 7:157-64.
[25]Pavan WJ, Hieter P, Reeves RH. Modification and transfer into an embryonal carcinoma cell line of a 360-kilobase human-derived yeast artificial chromosome. Mol Cell Biol 1990; 10: 4163-9.
[26]Murakami Y, Nobukuni T, Tamura K et al. Localization of tumor suppressor activity important in non-small cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci USA 1998; 95:8153-8.
[27]Kuramochi M, Fukuhara H, Nobukuni T et al. TSLC1 is a tumor suppressor gene in human non-small cell lung cancer. Nat Genet 2001;27:427-30.
[28]MasudaM, YagetaM, Fukuhara H, et al. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion [J]. J Bio Chem,2002,227:31014-31019.
[29]Wakayama T,Koami H,Ariga H,et al.Expression and functional characterization of the adhesion molecule spermatogenic immunoglobulin superfamily in the mouse testis[J].Biol Repord,2003,68(5):1755.
[30]Fujita E, Soyama A, Momoi T. RA175, which is the mouse ortholog of TSLC1,a tumor suppressor gene in human lung cancer,is a cell adhesion molecule[J].Exp Cell Res,2003,287(l):57.
[31]Biederer T. Bioinformatic characterrization of the Syn-CAM family of immunoglobulin-like domain-containing adhesion molecules [J]. Genomics,2006,87(1):139.
[32]Boles KS,Barchet W,Diacovo T,et al.The tumor suppressor TSLC1/NECL-2 triggers NK cell and CD8+T cell responses through the cell surface receptor CRTAM[J].Blood,2005,106(3):779.
[33]Galibert L,Diemer GS,Liu Z,et al.Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I restricted T-cell associated molecule[J].J Biol Chem,2005,280(23):21955.
[34]Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci,2003,94:575-81.
[35]Ito A, Okada M, Uchino K et al. Expression of the TSLC1 adhesion molecule in pulmonary epithelium and its down-regulation in pulmonary adenocarcinoma other than bronchioloalveolar carcinoma. Lab Invest,2003,83:1175-83.
[36]Mao X, Seidlitz E, Ghosh K, Murakami Y, Ghosh HP. The cytoplasmic domain is critical to the tumour suppressor activity of TSLC1 in nonsmall cell lung cancer. Cancer Res,2003,63: 7979-85.
[37]Hiroshi Fukuhara, Masami Kuramoehi, Takeshi Fukami, et al. Promoter Methylation of TSLC1 and Tumor Suppression by Its Gene Product in Human Prostate Cancer.Jpn.J.CancerRes.2002(93,)605-609
[38]Teiiehiro Honda, Gen Tamura, Takayoshi Waki, et al.HyPermethylation of the TSLC1 Gene Promoter in Primary Gastric Cancers and Gastric Cancer Cell Lines.JPn.J.CancerRes.2002(93),857-860.
[39]Jansen M, Fukushima N,Rosty C, et al. Aberrant methylation of the 5'CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs[J].Cancer Biol Ther,2002; 1:293-296.
[40]Takeshi Fukami,Hiroshi Fukuhara,Masami Kuramochi,et al. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines[J].Int J Cancer,2003; 107:53-59.
[41]Michael A.Caligiuri,Immune surveillance against common cancers:the great escape[J].Blood,2005;106(3):773-774.
[42]Ito T, Shimada Y, Hashimoto Y et al. Involvement of TSLC 1 in progression of esophageal squamous cell carcinoma. Cancer Res 2003; 63:6320-6.
[43]Uchino K, Ito A, Wakayama T et al. Clinical implication and prognostic significance of the tumor suppressor TSLC 1 gene detected inadenocarcinoma of the lung. Cancer 2003; 98:1002-7.
[44]Goto A, Niki T, Chi-pin L et al. Loss of TSLC expression in lung adenocarcinoma: Relationships with histological subtypes, sex and prognostic significance. Cancer Sci 2005; 96: 480-6.
[45]Murakami Y. Functional cloning of a tumor suppressor gene TSLC1 in human non-small cell lung cancer. Oncogene 2002; 21:6936-48.
[46]Fukami F, Fukuhara H, Kuramochi M et al. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer 2003; 107:53-9.
[47]Fukuhara H, Kuramochi M, Fukami T et al. Promoter methylation of the TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 2002; 93:605-9.
[48]Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer[J]. Nat Genet,2001,27 (4):427-430.
[49]王卡娜,许飞雪,李红芳,等TSLC1基因异常甲基化及与HPV的关系在宫颈癌发生发展中的意义[J].现代妇产科进展,2009,18(2)：94-98.
[50]Howard M, Sellors J, Kaczorowsli J. Optimizing the hybrid capture II human papillomavirus test to detect cervical intraepithelial neoplasia [J]. Obstet Gynecol, 2002,100 (5 Pt 1):972-980.
[51]Heller G, Geradts J, Ziegler B, et al. Down regulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer [J]. Breast Cancer Res Treat,2007,103 (3):283-291.
[52]Yang YX, Yang AH, Yang ZJ, et al. Involvement of tumor suppressor in lung cancer 1 gene expression in cervical carcinogenesis [J]. Int J Gynecol Cancer,2006,16 (5):1868-1872.
[53]Constandinou-Williams C, Collins SI, Roberts S, et al. Is human papillomavirus viral load a clinically useful predictive marker:a longitudinal study [J]. Cancer Epidemiol Biomarkers Prev, 2010,19 (3):832-837.
[1]Christothea Constandinou-Williams Stuart I Collins Sally Roberts,et al. Is human papillomavirus viral load a clinically useful predictive marker:a longitudinal study. Cancer Epidemiol Biomarkers Prev.2010 March; 19(3):832-837.
[2]Jo L. K. Cheung, Tak-Hong Cheung, Candy W. Y. Ng,et al. Analysis of Human Papillomavirus Type 18 Cervical Cancer Low-Grade Cervical Lesion to Invasive, Load and Integration Status from, J. Clin. Microbiol.2009,47(2):287.
[3]Brian Lowe*, Dominic O'Neil, Dirk Loeffert,et al. Distribution of Human papillomavirus load in clinical specimens, Journal of Virological Methods 173 (2011) 150-152.
[4]Yong Mi Kim, Jin Young Park, Kyung Mi Lee,et al. Does pretreatment HPV viral load correlate with prognosis in patients with early stage cervical carcinoma?[J] 2008 June J Gynecol Oncol Vol.19, No.2:113-116.
[5]Nelba Tabora, Annabelle Ferrera, Judith M. J. E. Bakkers,et al. High HPV 16 Viral Load is Associated with Increased Cervical Dysplasia in Honduran Women[J] Am. J. Trop. Med. Hyg., 78(5),2008, pp.843-846.
[7]Yuanchun Xul, Jorge Dotto2, Yiang Hui3,et al, High Grade Cervical Intraepithelial Neoplasia and Viral Load of High-Risk Human Papillomavirus:Significant Correlations in Patients of 22 Years Old or Younger[J]Int J Clin Exp Pathol (2009) 2,169-175.
[8]Agnetha M Josefsson, Patrik K E Magnusson, Nathalie Ylitalo.et al, Human Papillomavirus in Cervical Cancer Screening:Important Role as Biomarker[J]. Cancer Epidemiol Biomarkers Prev 2008;17:810-817.
[9]Agnihotram V Ramanakumar, Otelinda Goncalves, Harriet Richardson,et al, Human papillomavirus (HPV) types 16,18,31,45 DNA loads and HPV-16 integration in persistent and transient infections in young women. Ramanakumar et al. BMC Infectious Diseases 2010,10:326.
[10]Maelle Saunier, Sylvain Monnier-Benoit, Frederic Mauny,et al. with High-Grade Lesions or Cervical Identification of HPV16-Infected Women (HPV16) DNA Load and Physical State for Analysis Carcinoma.[J] J. Clin. Microbiol.2008, 46(11):3678.
[11]易为,王建六,李杏红,et al.高危型371负荷量与宫颈上皮内瘤样变级别、Ki-67和P16ink4a表达的关系及随访观察[J].癌症,2008,,2(5)：520-524.
[12]Kyehyun Nam, Sooho Chung, Jeongsig Kim,et al. Factors associated with HPV persistence after conization in patients with negative margins[J]. J Gynecol Onco June 20091 Vol.20, No. 2:91-95.
[13]Long Fu Xi,1,3 James P. Hughes,4 Zoe R. Edelstein,et al. Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-Year Follow-Up. The Journal of Infectious Diseases 2009; 200:1789-97.
[14]Gaelle A.V. Boulet, Caroline A.J. Horvath, Sarah Berghmans, et al. Human Papillomavirus in Cervical Cancer Screening:Important Role as Biomarker[J]. Cancer Epidemiol Biomarkers Prev 2008;17:810-817.
[15]Sara L. Bissett, Rebecca Howell-Jones, Craig Swift,el at. Human Papillomavirus Genotype Detection and Viral Load in Paired Genital and Urine Samples From Both Females and Males[J]. J. Med. Virol.2011,83:1744-1751.
[16]Xavier Carcopino, Mireille Henry, Julien Mancini,et al. Significance of HPV 16 and 18 Viral Load Quantitation in Women Referred for Colposcopy[J], Journal of Medical Virology,2010 (84):306-313.
[17]Albertus T. Hesselinkl, Johannes Berkhof2, Dani€elle A.M. Heideman,et al. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer[J]. Int. J. Cancer:2009(124),381-386.
[18]Yong Jung Song, Joo-Young Kim, Su-Kyoung Lee.et al, Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer[J]. Int. J. Cancer:2011(129),896-902.
[19]Helen Trottier, Silvaneide Ferreira, Patricia Thomann, et al. Human Papillomavirus Infection and Reinfection in Adult Women:the Role of Sexual Activity and Natural Immunity.[J] Cancer Res2010;70:8569-8577.
[20]M. Origoni.G. Carminati & S. Rolla. M. Clementi.et al. Human papillomavirus viral load expressed as relative light units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in atypical squamous cells of undetermined significance (ASCUS) cytology[J]. Eur J Clin Microbiol Infect Dis, Published online:01 March 2012.
[21]Jong Ha Hwang Jae Kwan Lee Tae Jin Kim.et al. The association between fruit and vegetable consumption and HPV viral load in high-risk HPV-positive women with cervical intraepithelial neoplasia[J]. Cancer Causes Control (2010) 21:51-59.
[22]Tomomi Yoshida,Takaaki Sano,Tetsunari Oyama.et al. Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma[J]. Virchows Arch (2009) 455:253-259.
[23]Rachel L. Winer, Tiffany G. Harris, Long Fu Xi.et al. Quantitative Human Papillomavirus 16 and 18 Levels in Incident Infections and Cervical Lesion Development[J]. Journal of Medical Virology 2009(81):713-721.
[24]Francesco Broccolo, Stefania Chiari, Andrea Piana,et al. Prevalence and Viral Load of Oncogenic Human Papillomavirus Types Associated With Cervical Carcinoma in a Population of North Italy[J]. Journal of Medical Virology 2009(81):278-287.
[25]D Mesher, A Szarewski, L Cadman.et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing:results from the HART study. British Journal of Cancer (2010)102,1405-1410.
[26]Jennifer R Moodley, Deborah Constant, Margaret Hoffman.et al. Human papillomavirus prevalence, viral load and pre-cancerouslesions of the cervix in women initiating highly active antiretroviral therapy in South Africa:a cross-sectional study. BMC Cancer 2009,9:275.
[27]N Munoz, G Hernandez-Suarez, F Me'ndezl,et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. British Journal of Cancer (2009) 100,1184-1190.
[28]Ann Nielsen, Susanne K. Kjaer, Christian Munk.et al. Persistence of High-Risk Human Papillomavirus Infection in a Population-Based Cohort of Danish Women, Journal of Medical Virology2010(82):616-623.
[29]Francois Coutleea, Helen Trottier, Simon Gagnona,et al. Low-risk human papillomavirus type 6 DNA load and integration in cervical samples from women with squamous intraepithelial lesions. Journal of Clinical Virology 45 (2009) 96-99.
[2]Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer:the size of the problem [J]. Best Pract Res Clin ObstetGynaecol,2006,20 (2):207-225.
[3]Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papillomavires 16 as a determinant for development of cervical carcinoma in situ:a nested case-control study[J].Lancet, 2000,355(9222):2189.
[6]丁素玲,高魁文.人乳头状瘤病毒感染与宫颈癌的研究进展[J].中国自然医学杂志,2005,10(2)：147.
[7]许娟秀,舒宽勇,熊树华,等.宫颈癌中表观遗传学的研究进展.国际妇产科学杂志,2008,35(3)：181.
[8]Shailja Pande,Neeraj Jain, Bhudev C. Dasl, et al. Human papillomavirus type 16 variant analysis of E6, E7. and L1 genes and long control region in biopsy samples from cervical cancer patients in North India [J]. Clinical Microbiology,2008,46 (3):1060.
[9]林晓华,吴宁,侯丽辉,等.人乳头瘤病毒与宫颈肿瘤关系的研究进展(J).医学研究生学报,2006,19(2)：183.
[10]刘宏图,人乳头瘤病毒感染与宫颈癌进展的相关性[J].中国实用妇科与产科杂志,2010,26(5)：324-327.
[11]邵华江,石一复,等.人乳头瘤病毒与子宫颈癌防治进展[J].实用肿瘤杂志,2010,26(1)：5-7.
[12]Poprdvu NC, Zimonjic D, Dipaolo JA. Viral intergration,fragilesites,and protooncogenes in human meoplasia [J]. Hum Gen,1990,84:383-386.
[13]Kalantari M, Blennow E,Hagmar B, et al. Physical state of HPV16 and chromosomal mapping of the integrated from in cervical carcinomas[J].Diagn-Mol-Pathol,2001,10(1):46-54.
[14]Thorland EC, Myers SL, Persing DH, et al. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites[J]. Cancer-Res,2000,60 (21):5916-21.
[15]Horland EC, Myers SL, Gostout BS, et al. cell surface-bindingmotifs of L2 that facilitate papillovirus infection[J]. J Virol,2003,77(6):3531-41.
[16]Wentzensen N, Vinokurov S, von Knebel doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the male lower genital tract[J]. Cancer Res,2004,64:3878-3884.
[17]李华,高国兰.HPV与宫颈癌的研究进展[J].实用癌症杂志,2007,22(4)：420.
[18]李素红,王全红.HPV与宫颈癌的研究进展[J].肿瘤研究与临床,2005,17(6)：430.
[19]孙志辉,岳天孚.人乳头瘤病毒16/18型与宫颈癌[J].国际妇产科学杂志,2010,(4)：119-123.
[20]Long Fu Xi,1,3 James P. Hughes,4 Zoe R. Edelstein,et al. Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-Year Follow-Up. The Journal of Infectious Diseases 2009; 200:1789-97.
[21]Wu YP, Chen YL, Li LY, et al. Associations of high□risk HPV types and viral load with cervical cancer in China[J]. J Clin Virol 2006,35:264-269.
[22]Xavier Carcopino, Mireille Henry, Julien Mancini,et al. Significance of HPV 16 and 18 Viral Load Quantitation in Women Referred for Colposcopy[J], Journal of Medical Virology,2010 (84):306-313.
[23]Rachel L. Winer, Tiffany G. Harris, Long Fu Xi.et al. Quantitative Human Papillomavirus 16 and 18 Levels in Incident Infections and Cervical Lesion Development[J]. Journal of Medical Virology 2009(81):713-721.
[24]Satoh H, Lamb PW, Dong JT et al. Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. Mol Carcinog 1993; 7:157-64.
[25]Pavan WJ, Hieter P, Reeves RH. Modification and transfer into an embryonal carcinoma cell line of a 360-kilobase human-derived yeast artificial chromosome. Mol Cell Biol 1990; 10: 4163-9.
[26]Murakami Y, Nobukuni T, Tamura K et al. Localization of tumor suppressor activity important in non-small cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci USA 1998; 95:8153-8.
[27]Kuramochi M, Fukuhara H, Nobukuni T et al. TSLC1 is a tumor suppressor gene in human non-small cell lung cancer. Nat Genet 2001;27:427-30.
[28]MasudaM, YagetaM, Fukuhara H, et al. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion [J]. J Bio Chem,2002,227:31014-31019.
[29]Wakayama T,Koami H,Ariga H,et al.Expression and functional characterization of the adhesion molecule spermatogenic immunoglobulin superfamily in the mouse testis[J].Biol Repord,2003,68(5):1755.
[30]Fujita E, Soyama A, Momoi T. RA175, which is the mouse ortholog of TSLC1,a tumor suppressor gene in human lung cancer,is a cell adhesion molecule[J].Exp Cell Res,2003,287(l):57.
[31]Biederer T. Bioinformatic characterrization of the Syn-CAM family of immunoglobulin-like domain-containing adhesion molecules [J]. Genomics,2006,87(1):139.
[32]Boles KS,Barchet W,Diacovo T,et al.The tumor suppressor TSLC1/NECL-2 triggers NK cell and CD8+T cell responses through the cell surface receptor CRTAM[J].Blood,2005,106(3):779.
[33]Galibert L,Diemer GS,Liu Z,et al.Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I restricted T-cell associated molecule[J].J Biol Chem,2005,280(23):21955.
[34]Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci,2003,94:575-81.
[35]Ito A, Okada M, Uchino K et al. Expression of the TSLC1 adhesion molecule in pulmonary epithelium and its down-regulation in pulmonary adenocarcinoma other than bronchioloalveolar carcinoma. Lab Invest,2003,83:1175-83.
[36]Mao X, Seidlitz E, Ghosh K, Murakami Y, Ghosh HP. The cytoplasmic domain is critical to the tumour suppressor activity of TSLC1 in nonsmall cell lung cancer. Cancer Res,2003,63: 7979-85.
[37]Hiroshi Fukuhara, Masami Kuramoehi, Takeshi Fukami, et al. Promoter Methylation of TSLC1 and Tumor Suppression by Its Gene Product in Human Prostate Cancer.Jpn.J.CancerRes.2002(93,)605-609
[38]Teiiehiro Honda, Gen Tamura, Takayoshi Waki, et al.HyPermethylation of the TSLC1 Gene Promoter in Primary Gastric Cancers and Gastric Cancer Cell Lines.JPn.J.CancerRes.2002(93),857-860.
[39]Jansen M, Fukushima N,Rosty C, et al. Aberrant methylation of the 5'CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs[J].Cancer Biol Ther,2002; 1:293-296.
[40]Takeshi Fukami,Hiroshi Fukuhara,Masami Kuramochi,et al. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines[J].Int J Cancer,2003; 107:53-59.
[41]Michael A.Caligiuri,Immune surveillance against common cancers:the great escape[J].Blood,2005;106(3):773-774.
[42]Ito T, Shimada Y, Hashimoto Y et al. Involvement of TSLC 1 in progression of esophageal squamous cell carcinoma. Cancer Res 2003; 63:6320-6.
[43]Uchino K, Ito A, Wakayama T et al. Clinical implication and prognostic significance of the tumor suppressor TSLC 1 gene detected inadenocarcinoma of the lung. Cancer 2003; 98:1002-7.
[44]Goto A, Niki T, Chi-pin L et al. Loss of TSLC expression in lung adenocarcinoma: Relationships with histological subtypes, sex and prognostic significance. Cancer Sci 2005; 96: 480-6.
[45]Murakami Y. Functional cloning of a tumor suppressor gene TSLC1 in human non-small cell lung cancer. Oncogene 2002; 21:6936-48.
[46]Fukami F, Fukuhara H, Kuramochi M et al. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer 2003; 107:53-9.
[47]Fukuhara H, Kuramochi M, Fukami T et al. Promoter methylation of the TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 2002; 93:605-9.
[48]Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer[J]. Nat Genet,2001,27 (4):427-430.
[49]王卡娜,许飞雪,李红芳,等TSLC1基因异常甲基化及与HPV的关系在宫颈癌发生发展中的意义[J].现代妇产科进展,2009,18(2)：94-98.
[50]Howard M, Sellors J, Kaczorowsli J. Optimizing the hybrid capture II human papillomavirus test to detect cervical intraepithelial neoplasia [J]. Obstet Gynecol, 2002,100 (5 Pt 1):972-980.
[51]Heller G, Geradts J, Ziegler B, et al. Down regulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer [J]. Breast Cancer Res Treat,2007,103 (3):283-291.
[52]Yang YX, Yang AH, Yang ZJ, et al. Involvement of tumor suppressor in lung cancer 1 gene expression in cervical carcinogenesis [J]. Int J Gynecol Cancer,2006,16 (5):1868-1872.
[53]Constandinou-Williams C, Collins SI, Roberts S, et al. Is human papillomavirus viral load a clinically useful predictive marker:a longitudinal study [J]. Cancer Epidemiol Biomarkers Prev, 2010,19 (3):832-837.
[1]Christothea Constandinou-Williams Stuart I Collins Sally Roberts,et al. Is human papillomavirus viral load a clinically useful predictive marker:a longitudinal study. Cancer Epidemiol Biomarkers Prev.2010 March; 19(3):832-837.
[2]Jo L. K. Cheung, Tak-Hong Cheung, Candy W. Y. Ng,et al. Analysis of Human Papillomavirus Type 18 Cervical Cancer Low-Grade Cervical Lesion to Invasive, Load and Integration Status from, J. Clin. Microbiol.2009,47(2):287.
[3]Brian Lowe*, Dominic O'Neil, Dirk Loeffert,et al. Distribution of Human papillomavirus load in clinical specimens, Journal of Virological Methods 173 (2011) 150-152.
[4]Yong Mi Kim, Jin Young Park, Kyung Mi Lee,et al. Does pretreatment HPV viral load correlate with prognosis in patients with early stage cervical carcinoma?[J] 2008 June J Gynecol Oncol Vol.19, No.2:113-116.
[5]Nelba Tabora, Annabelle Ferrera, Judith M. J. E. Bakkers,et al. High HPV 16 Viral Load is Associated with Increased Cervical Dysplasia in Honduran Women[J] Am. J. Trop. Med. Hyg., 78(5),2008, pp.843-846.
[7]Yuanchun Xul, Jorge Dotto2, Yiang Hui3,et al, High Grade Cervical Intraepithelial Neoplasia and Viral Load of High-Risk Human Papillomavirus:Significant Correlations in Patients of 22 Years Old or Younger[J]Int J Clin Exp Pathol (2009) 2,169-175.
[8]Agnetha M Josefsson, Patrik K E Magnusson, Nathalie Ylitalo.et al, Human Papillomavirus in Cervical Cancer Screening:Important Role as Biomarker[J]. Cancer Epidemiol Biomarkers Prev 2008;17:810-817.
[9]Agnihotram V Ramanakumar, Otelinda Goncalves, Harriet Richardson,et al, Human papillomavirus (HPV) types 16,18,31,45 DNA loads and HPV-16 integration in persistent and transient infections in young women. Ramanakumar et al. BMC Infectious Diseases 2010,10:326.
[10]Maelle Saunier, Sylvain Monnier-Benoit, Frederic Mauny,et al. with High-Grade Lesions or Cervical Identification of HPV16-Infected Women (HPV16) DNA Load and Physical State for Analysis Carcinoma.[J] J. Clin. Microbiol.2008, 46(11):3678.
[11]易为,王建六,李杏红,et al.高危型371负荷量与宫颈上皮内瘤样变级别、Ki-67和P16ink4a表达的关系及随访观察[J].癌症,2008,,2(5)：520-524.
[12]Kyehyun Nam, Sooho Chung, Jeongsig Kim,et al. Factors associated with HPV persistence after conization in patients with negative margins[J]. J Gynecol Onco June 20091 Vol.20, No. 2:91-95.
[13]Long Fu Xi,1,3 James P. Hughes,4 Zoe R. Edelstein,et al. Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-Year Follow-Up. The Journal of Infectious Diseases 2009; 200:1789-97.
[14]Gaelle A.V. Boulet, Caroline A.J. Horvath, Sarah Berghmans, et al. Human Papillomavirus in Cervical Cancer Screening:Important Role as Biomarker[J]. Cancer Epidemiol Biomarkers Prev 2008;17:810-817.
[15]Sara L. Bissett, Rebecca Howell-Jones, Craig Swift,el at. Human Papillomavirus Genotype Detection and Viral Load in Paired Genital and Urine Samples From Both Females and Males[J]. J. Med. Virol.2011,83:1744-1751.
[16]Xavier Carcopino, Mireille Henry, Julien Mancini,et al. Significance of HPV 16 and 18 Viral Load Quantitation in Women Referred for Colposcopy[J], Journal of Medical Virology,2010 (84):306-313.
[17]Albertus T. Hesselinkl, Johannes Berkhof2, Dani€elle A.M. Heideman,et al. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer[J]. Int. J. Cancer:2009(124),381-386.
[18]Yong Jung Song, Joo-Young Kim, Su-Kyoung Lee.et al, Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer[J]. Int. J. Cancer:2011(129),896-902.
[19]Helen Trottier, Silvaneide Ferreira, Patricia Thomann, et al. Human Papillomavirus Infection and Reinfection in Adult Women:the Role of Sexual Activity and Natural Immunity.[J] Cancer Res2010;70:8569-8577.
[20]M. Origoni.G. Carminati & S. Rolla. M. Clementi.et al. Human papillomavirus viral load expressed as relative light units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in atypical squamous cells of undetermined significance (ASCUS) cytology[J]. Eur J Clin Microbiol Infect Dis, Published online:01 March 2012.
[21]Jong Ha Hwang Jae Kwan Lee Tae Jin Kim.et al. The association between fruit and vegetable consumption and HPV viral load in high-risk HPV-positive women with cervical intraepithelial neoplasia[J]. Cancer Causes Control (2010) 21:51-59.
[22]Tomomi Yoshida,Takaaki Sano,Tetsunari Oyama.et al. Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma[J]. Virchows Arch (2009) 455:253-259.
[23]Rachel L. Winer, Tiffany G. Harris, Long Fu Xi.et al. Quantitative Human Papillomavirus 16 and 18 Levels in Incident Infections and Cervical Lesion Development[J]. Journal of Medical Virology 2009(81):713-721.
[24]Francesco Broccolo, Stefania Chiari, Andrea Piana,et al. Prevalence and Viral Load of Oncogenic Human Papillomavirus Types Associated With Cervical Carcinoma in a Population of North Italy[J]. Journal of Medical Virology 2009(81):278-287.
[25]D Mesher, A Szarewski, L Cadman.et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing:results from the HART study. British Journal of Cancer (2010)102,1405-1410.
[26]Jennifer R Moodley, Deborah Constant, Margaret Hoffman.et al. Human papillomavirus prevalence, viral load and pre-cancerouslesions of the cervix in women initiating highly active antiretroviral therapy in South Africa:a cross-sectional study. BMC Cancer 2009,9:275.
[27]N Munoz, G Hernandez-Suarez, F Me'ndezl,et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. British Journal of Cancer (2009) 100,1184-1190.
[28]Ann Nielsen, Susanne K. Kjaer, Christian Munk.et al. Persistence of High-Risk Human Papillomavirus Infection in a Population-Based Cohort of Danish Women, Journal of Medical Virology2010(82):616-623.
[29]Francois Coutleea, Helen Trottier, Simon Gagnona,et al. Low-risk human papillomavirus type 6 DNA load and integration in cervical samples from women with squamous intraepithelial lesions. Journal of Clinical Virology 45 (2009) 96-99.